M&A/Shareholder vote/2026/Eos SENOLYTIX Inc.

Eos SENOLYTIX Inc. PULM

Pulmatrix, Inc. is buying Eos SENOLYTIX Inc. (PULM), paying holders in stock, expected to close Q4 2026. Develops medicines that target the root biological mechanisms of aging to improve healthspan in the emerging field of gerotherapeutics.

Holders get
Stock
approximately 8.55 shares of Pulmatrix common stock per share of Eos capital stock
Deal value
Not given
Expected close
Q4 2026
Status
Approved by holders
Checked
See the filing →

Filed

The deal

Pulmatrix, Inc. is acquiring Eos SENOLYTIX Inc., a developer of medicines targeting root biological mechanisms of aging to improve healthspan in gerotherapeutics. Eos stockholders will receive approximately 8.55 shares of Pulmatrix common stock per share of Eos capital stock.

The deal is expected to close in the fourth quarter of 2026. It requires Nasdaq approval for listing of Combined Company, Pulmatrix stockholder approval of Proposal Nos. 1, 2 and 3, Eos to receive aggregate gross cash proceeds of at least $13,000,000 from financing transactions, and Eos stockholder approval by written consent.

What has happened

Agreement signed · See the filing
Holders sent the terms and a meeting date
Holders approved the deal · Pulmatrix stockholders approved the issuance of shares for the merger and related proposals, with 1,410,737 votes for and 172,166 against Proposal No. 1. · See the filing

What must happen first

Nasdaq approval for listing of Combined Company
Pulmatrix stockholder approval of Proposal Nos. 1, 2 and 3
Eos to receive aggregate gross cash proceeds of at least $13,000,000 from financing transactions
Eos stockholder approval by written consent

The board says

FOR each of Proposal Nos. 1, 2, 3, 4, 6, 7, 8 and 9, FOR director nominees in Proposal No. 5, EVERY THREE YEARS for Proposal No. 7